Leidos Holdings, Inc. Q2 2026 Earnings Call Summary
Leidos Holdings reported record Q2 2026 revenue of $4.6 billion and a 1.1 book-to-bill ratio, with Defense at a 2.2 book-to-bill. Full-year revenue guidance was raised by $100 million at the midpoint. Health faces VA incentive payment suspension, while Homeland grew 32%. Capex guidance was cut to about $250 million and share repurchases were authorized.
How this was made
The 30-second read
Why it matters
Traders can reassess 2026 earnings quality by combining the guidance raise with explicit margin headwinds (VA incentive suspension) and Defense Health Agency acquisition strategy changes.
Market read
Company-specific guidance and contract transition details can drive near-term positioning around 2026 revenue and segment margin expectations.
What to watch
The article excludes the pending SES joint venture from current guidance, and it flags a shift toward fixed-price contracting, which can change margin volatility even if revenue grows.
Background
Leidos’ Q2 2026 call frames performance across Defense, Health, and Homeland, with guidance updates tied to NorthStar 2030 and contract/program transitions.
Ticker impact
Leidos raised full-year 2026 revenue guidance by $100 million at the midpoint and outlined Health and Defense contract/profit headwinds.
Likely supports an upside bias from the guidance raise, but Health profitability and VA incentive suspension risk can cap the move.
The article provides multiple concrete, company-specific datapoints: raised revenue guidance, VA incentive suspension expected to last the year, and a Defense Health Agency sole-source bridge transition, which together affect segment margins and bookings.
Market effects
Defense IT and mission systems integrators may see read-across demand for integration services, while Health services contractors face reimbursement/incentive policy risk.
Limited direct regional impact; Huntsville workforce scaling is a localized operational signal.
Primarily US government contracting dynamics; limited global spillover beyond defense/health procurement trends.
Counterpoint
The raised revenue guidance may not translate into earnings upside if Health profitability is structurally pressured by the VA incentive suspension and contract transitions.
Key entities
- public_companyLeidos Holdings, Inc.
Defense, Health, and Homeland contractor providing Q2 2026 performance and raised 2026 revenue guidance, plus segment-specific risks.
- government_agencyU.S. Department of Veterans Affairs (VA)
Suspended incentive payments for medical disability exams, expected to last the remainder of 2026 and pressure Health profitability.
- government_agencyDefense Health Agency (DHA)
Finalizing long-term acquisition strategy, with MHS GENESIS transitioning to a sole-source bridge contract.
- public_companyAnalogic
Named as the partner in a pending SES joint venture expected to close later in 2026.
